Madrigal Pharmaceuticals, Inc.
MDGL
$307.78
-$13.32-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 180.13M | 76.81M | 14.64M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 180.13M | 76.81M | 14.64M | -- | -- |
| Cost of Revenue | 6.23M | 2.79M | 636.00K | -- | -- |
| Gross Profit | 173.90M | 74.03M | 14.00M | -- | -- |
| SG&A Expenses | 435.06M | 340.37M | 260.37M | 172.76M | 108.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 678.01M | 624.87M | 544.92M | 454.20M | 380.50M |
| Operating Income | -497.87M | -548.05M | -530.28M | -454.20M | -380.50M |
| Income Before Tax | -465.89M | -518.67M | -510.45M | -444.28M | -373.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -465.89 | -518.67 | -510.45 | -444.28 | -373.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -465.89M | -518.67M | -510.45M | -444.28M | -373.63M |
| EBIT | -497.87M | -548.05M | -530.28M | -454.20M | -380.50M |
| EBITDA | -496.78M | -547.18M | -529.57M | -453.63M | -379.97M |
| EPS Basic | -22.11 | -25.07 | -25.50 | -23.08 | -19.94 |
| Normalized Basic EPS | -13.82 | -15.67 | -15.94 | -14.43 | -12.46 |
| EPS Diluted | -22.11 | -25.07 | -25.50 | -23.08 | -19.94 |
| Normalized Diluted EPS | -13.82 | -15.67 | -15.94 | -14.43 | -12.46 |
| Average Basic Shares Outstanding | 85.08M | 82.91M | 79.64M | 76.55M | 74.74M |
| Average Diluted Shares Outstanding | 85.08M | 82.91M | 79.64M | 76.55M | 74.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |